DK1202746T3 - NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer - Google Patents

NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer

Info

Publication number
DK1202746T3
DK1202746T3 DK00950930T DK00950930T DK1202746T3 DK 1202746 T3 DK1202746 T3 DK 1202746T3 DK 00950930 T DK00950930 T DK 00950930T DK 00950930 T DK00950930 T DK 00950930T DK 1202746 T3 DK1202746 T3 DK 1202746T3
Authority
DK
Denmark
Prior art keywords
nsaid
inhibition
treatment
colorectal cancer
kinase inhibitor
Prior art date
Application number
DK00950930T
Other languages
Danish (da)
English (en)
Inventor
Philip Frost
Carolyn Mary Discafani-Marro
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1202746T3 publication Critical patent/DK1202746T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00950930T 1999-08-12 2000-08-02 NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer DK1202746T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12

Publications (1)

Publication Number Publication Date
DK1202746T3 true DK1202746T3 (da) 2007-01-02

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00950930T DK1202746T3 (da) 1999-08-12 2000-08-02 NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer

Country Status (24)

Country Link
EP (1) EP1202746B1 (ru)
JP (1) JP2003507342A (ru)
KR (1) KR20020018201A (ru)
CN (1) CN1229142C (ru)
AR (1) AR029763A1 (ru)
AT (1) ATE341341T1 (ru)
AU (1) AU783116B2 (ru)
BR (1) BR0013219A (ru)
CA (1) CA2380904C (ru)
CZ (1) CZ2002474A3 (ru)
DE (1) DE60031127T2 (ru)
DK (1) DK1202746T3 (ru)
EA (1) EA006876B1 (ru)
ES (1) ES2272305T3 (ru)
HK (1) HK1042244A1 (ru)
HU (1) HUP0203162A3 (ru)
IL (1) IL147913A0 (ru)
MX (1) MXPA02001448A (ru)
NO (1) NO20020663L (ru)
NZ (1) NZ517120A (ru)
PL (1) PL353267A1 (ru)
PT (1) PT1202746E (ru)
WO (1) WO2001012227A1 (ru)
ZA (1) ZA200201156B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
BR0109165A (pt) * 2000-03-13 2003-04-22 American Cyanamid Co Método de tratamento de pólipos colÈnicos
EP1412367A4 (en) 2001-06-21 2006-05-03 Ariad Pharma Inc NEW CHINOLINE AND ITS USE
US7501516B2 (en) 2001-07-16 2009-03-10 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
JP2005506366A (ja) * 2001-10-25 2005-03-03 ノバルティス アクチエンゲゼルシャフト 選択的シクロオキシゲナーゼ−２阻害剤を含む組合せ剤
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE60313339T2 (de) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
DE60318089T2 (de) 2002-10-09 2008-12-04 Critical Outcome Technologies, Inc. Protein-tyrosine-kinase-inhibitoren
EP1570080A4 (en) * 2002-11-15 2006-03-01 Genomic Health Inc GENE EXPRESSION PROFILING OF EGFR-POSITIVE CANCER DISEASE
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
CN102924458B (zh) 2004-04-02 2014-11-05 Osi制药有限责任公司 6,6-双环取代的杂双环蛋白激酶抑制剂
ME01267B (me) 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
NZ551431A (en) 2004-06-03 2010-04-30 Hoffmann La Roche Treatment with cisplatin and an EGFR-inhibitor
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
PL2245026T3 (pl) 2008-02-07 2013-01-31 Boehringer Ingelheim Int Spirocykliczne heterocykle, leki zawierające te związki, ich zastosowanie i sposób ich produkcji
ES2444128T3 (es) 2008-05-13 2014-02-24 Astrazeneca Ab Nueva SAL-554
JP2011520970A (ja) 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
PL387312A1 (pl) * 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
CA2752826A1 (en) 2009-04-20 2010-10-28 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
AU2012262014B2 (en) * 2011-06-01 2016-07-14 Janus Biotherapeutics, Inc. Novel immune system modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200000488A1 (ru) * 1997-11-04 2000-10-30 Пфайзер Продактс Инк. Замена катехина на биоизостеру индазола в терапевтически активных соединениях
PL340800A1 (en) * 1997-11-06 2001-02-26 American Cyanamid Co Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps

Also Published As

Publication number Publication date
MXPA02001448A (es) 2002-07-02
PL353267A1 (en) 2003-11-03
IL147913A0 (en) 2002-08-14
AU6395900A (en) 2001-03-13
ES2272305T3 (es) 2007-05-01
AR029763A1 (es) 2003-07-16
ZA200201156B (en) 2003-05-12
ATE341341T1 (de) 2006-10-15
EP1202746B1 (en) 2006-10-04
JP2003507342A (ja) 2003-02-25
HUP0203162A3 (en) 2006-07-28
CN1370080A (zh) 2002-09-18
CA2380904C (en) 2009-02-10
EP1202746A1 (en) 2002-05-08
PT1202746E (pt) 2007-01-31
DE60031127D1 (de) 2006-11-16
KR20020018201A (ko) 2002-03-07
EA006876B1 (ru) 2006-04-28
EA200200246A1 (ru) 2002-08-29
WO2001012227A1 (en) 2001-02-22
AU783116B2 (en) 2005-09-29
CA2380904A1 (en) 2001-02-22
HK1042244A1 (zh) 2002-08-09
NO20020663D0 (no) 2002-02-11
CN1229142C (zh) 2005-11-30
NZ517120A (en) 2004-10-29
HUP0203162A2 (hu) 2003-01-28
DE60031127T2 (de) 2007-02-01
NO20020663L (no) 2002-04-09
BR0013219A (pt) 2002-04-23
CZ2002474A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
DK1202746T3 (da) NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
NO20002166D0 (no) Anvendelse av quinazolinderivater som tyrosinkinaseinhibitorer for behandling av kolonpolypper
DK1263503T3 (da) Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypper
NO20024610L (no) Synergistiske metoder og blandinger for behandling av kreft
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1165078T3 (da) Fremgangsmåder til induktion af cancercelledöd og tumorregression
NO20021820D0 (no) Tyrosinkinaseinhibitorer
IS7233A (is) Kínasólín afleiður til meðhöndlunar á afbrigðilegum frumuvexti
DK1576132T3 (da) Nukleinsyrer benævnt 273p4b7 og anvendelse heraf til detektering af cancer
NO20012583D0 (no) Quinoliner og quinoksalinforbindelser som PDGF-R- og/eller LCK-tyrosinkinase-inhibitorer
ATE412070T1 (de) Prognose von kolorektalem krebs
NO20031582L (no) Aryl eller heteroaryl fusjonert med imidazolforbindelser som anti-inflammatoriske og smertestillende midler
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
NO20022245L (no) Onkolyttiske kombinasjoner for behandling av cancer
NO20020358L (no) Anvendelse av etodolac til behandling av kreft
DK1694364T3 (da) System til behandling og forebyggelse af brystcancer
NO20034350D0 (no) Optisk avbilding av kolorektal kreft
AU2002311859A1 (en) Compositions and methods for treating colorectal polyps and cancer
DK1239862T3 (da) Farmaceutisk præparat indeholdende cytostatika og eletronacceptorer til behandling af kræft
DK1512758T3 (da) Prognose af colorektal cancer
DK1140147T3 (da) hCG-terapi til behandling af metastatisk brystcancer
SI1202746T1 (sl) FARMACEVTSKA OBLIKA, KI VSEBUJE NSAID in ZAVIRALEC KINAZE EGFR, ZA ZDRAVLJENJE ALI PREPRECEVANJE POLIPOV DEBELEGA CREVESA IN KOLOREKTALNEGA RAKA